Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

Sponsor

University of Arizona (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06110078

Collaborator

(none)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Acetazolamide is a drug that is approved by the FDA for treating various conditions like epilepsy, altitude sickness, and glaucoma. Acetazolamide works by inhibiting an enzyme called carbonic anhydrase, which is important for many essential processes in our body. For example, carbonic anhydrase is needed to transport carbon dioxide in our blood which is essential for respiration.

One of the interesting effects of acetazolamide is that it reduces the taste of carbonation, making carbonated drinks like soda taste flat and or like soapy water. This effect has been noticed by hikers using the drug for mountain sickness treatment. It's believed that carbonic anhydrase inhibitors decrease the levels of carbonic acid in our mouths, which in turn reduces and changes the perception of carbonation taste.

It was hypothesized that this side effect of acetazolamide could be used to help people cut down on soda consumption. Since soda has been linked to health issues like obesity and type 2 diabetes, reducing its intake could be beneficial. In a case study, a person who took low-dose acetazolamide for six weeks experienced weight loss and found it easier to avoid carbonated drinks.

We are proposing a study to explore the effects of using acetazolamide as an oral rinse to decrease soda intake. The use of acetazolamide as an oral rinse has yet to be tested and is a possible way to decrease the taste of carbonation while also decreasing the side effects of the drug. Our plan is to use different doses of the rinse on participants and monitor their soda consumption and body mass index (BMI) changes.

In summary, acetazolamide, a drug with various medical uses, could potentially help people reduce soda consumption by altering the taste of carbonation.

Condition or Disease	Intervention/Treatment	Phase
Obesity	Drug: Acetazolamide	Early Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

44 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Participant)

Primary Purpose:

Treatment

Official Title:

Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

Anticipated Study Start Date :

Dec 1, 2023

Anticipated Primary Completion Date :

May 1, 2024

Anticipated Study Completion Date :

May 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group 1 Daily oral acetazolamide mouth rinse	Drug: Acetazolamide Oral rinse with acetazolamide (not taken orally)
Experimental: Group 2 Twice daily oral acetazolamide mouth rinse	Drug: Acetazolamide Oral rinse with acetazolamide (not taken orally)
Placebo Comparator: Group 3 Placebo mouth wash daily	Drug: Acetazolamide Oral rinse with acetazolamide (not taken orally)
Placebo Comparator: Group 4 Twice daily placebo mouth wash	Drug: Acetazolamide Oral rinse with acetazolamide (not taken orally)

Outcome Measures

Primary Outcome Measures

Soda intake [3 weeks]
Total soda/carbonated beverage intake per week

Secondary Outcome Measures

Weight [3 weeks]
BMI/weight

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 100 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age ≥ 18 years.
Consumes on average ≥ 7 sodas per week
Healthy and without a history of significant neurological, liver, renal, cardiac or pulmonary disease.
No allergy to sulfa drugs or aspirin (contained in Alka Seltzer).
Ability to provide informed consent.

Exclusion Criteria:

Healthy adults, UA students, UA faculty and staff Exclusion Criteria:

Pregnant or lactating women.
Prisoners.
Refugees.
Cognitive impairment.
Chronic illness.
Allergy to sulfa drugs or aspirin.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

University of Arizona

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

C. William Heise MD, Assistant Professor, University of Arizona

ClinicalTrials.gov Identifier:

NCT06110078

Other Study ID Numbers:

STUDY00003535

First Posted:

Oct 31, 2023

Last Update Posted:

Oct 31, 2023

Last Verified:

Oct 1, 2023

Studies a U.S. FDA-regulated Drug Product:

Yes

Studies a U.S. FDA-regulated Device Product:

Product Manufactured in and Exported from the U.S.:

Additional relevant MeSH terms:

Acetazolamide

Study Results

No Results Posted as of Oct 31, 2023